Copy to clipboard 
Smith+Nephew has appointed Dr. Deepak Nath as its new Chief Executive Officer, succeeding Roland Diggelmann, who will step down by mutual agreement. Dr. Nath takes on his new role in April 2022.
Dr. Nath joins Smith+Nephew from Siemens Healthineers (2018-2022) where most recently he was President of the Diagnostics business segment responsible for $6 billion of sales and 15,000 employees. During his time there, he led a major program to drive growth and margin expansion through improved execution and a strong results-focused culture.
Prior to Siemens Healthineers, Dr. Nath held a number of senior roles at Abbott Laboratories (2007-2017) spanning R&D, marketing, commercial and divisional leadership, rising to President of Abbott Vascular and an Executive Officer of Abbott Laboratories. At Abbott, he significantly improved performance of the Vascular business and had a leadership role in the $28 billion acquisition of St Jude Medical.
Dr. Nath also worked for Amgen (2004-2007), McKinsey and Company (2000-2004) and as a scientist at the Lawrence Livermore National Laboratory.
Roland Diggelmann was appointed CEO at Smith+Nephew in late 2019, following the stepdown of then-CEO Namal Nawana.
Since his appointment, Mr. Diggelmann has navigated Smith+Nephew through the challenges presented by COVID while also building a stronger platform for future growth, including increasing investment in R&D and launching multiple new products.
During Mr. Diggelmann’s tenure, Smith+Nephew acquired the extremity orthopedics business of Integra LifeSciences, and more recently, purchased Engage Surgical, developer of the only cementless unicompartmental knee system commercially available in the U.S.
He also oversaw the launch of the CORI handheld robot as well as renewed success in the company’s hip and sports medicine equipment lines. However, under Mr. Diggelmann’s stewardship, Smith+Nephew never fully leveraged its sports medicine and joint replacement synergies in the ASC environment. Supply chain problems hampered the company’s recovery efforts in 2021. Smith+Nephew has also been a share loser in knee replacement due to its late entry into the cementless knee market.
Source: Smith+Nephew
Smith+Nephew has appointed Dr. Deepak Nath as its new Chief Executive Officer, succeeding Roland Diggelmann, who will step down by mutual agreement. Dr. Nath takes on his new role in April 2022.
Dr. Nath joins Smith+Nephew from Siemens Healthineers (2018-2022) where most recently he was President of the Diagnostics business segment responsible...
Smith+Nephew has appointed Dr. Deepak Nath as its new Chief Executive Officer, succeeding Roland Diggelmann, who will step down by mutual agreement. Dr. Nath takes on his new role in April 2022.
Dr. Nath joins Smith+Nephew from Siemens Healthineers (2018-2022) where most recently he was President of the Diagnostics business segment responsible for $6 billion of sales and 15,000 employees. During his time there, he led a major program to drive growth and margin expansion through improved execution and a strong results-focused culture.
Prior to Siemens Healthineers, Dr. Nath held a number of senior roles at Abbott Laboratories (2007-2017) spanning R&D, marketing, commercial and divisional leadership, rising to President of Abbott Vascular and an Executive Officer of Abbott Laboratories. At Abbott, he significantly improved performance of the Vascular business and had a leadership role in the $28 billion acquisition of St Jude Medical.
Dr. Nath also worked for Amgen (2004-2007), McKinsey and Company (2000-2004) and as a scientist at the Lawrence Livermore National Laboratory.
Roland Diggelmann was appointed CEO at Smith+Nephew in late 2019, following the stepdown of then-CEO Namal Nawana.
Since his appointment, Mr. Diggelmann has navigated Smith+Nephew through the challenges presented by COVID while also building a stronger platform for future growth, including increasing investment in R&D and launching multiple new products.
During Mr. Diggelmann’s tenure, Smith+Nephew acquired the extremity orthopedics business of Integra LifeSciences, and more recently, purchased Engage Surgical, developer of the only cementless unicompartmental knee system commercially available in the U.S.
He also oversaw the launch of the CORI handheld robot as well as renewed success in the company’s hip and sports medicine equipment lines. However, under Mr. Diggelmann’s stewardship, Smith+Nephew never fully leveraged its sports medicine and joint replacement synergies in the ASC environment. Supply chain problems hampered the company’s recovery efforts in 2021. Smith+Nephew has also been a share loser in knee replacement due to its late entry into the cementless knee market.
Source: Smith+Nephew
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
